Enlarge / Ian Read, chairman and chief executive officer of Pfizer Inc. (credit: Getty | Bloomberg)
As drug giant Pfizer Inc. hiked the price of dozens of drugs in 2017, it also jacked up the compensation of CEO Ian Read by 61 percent, putting his total compensation at $27.9 million, according to financial filings reported by Bloomberg.
Pfizer’s board reportedly approved the compensation boost because they saw it as a “compelling incentive” to keep Read from retiring. He turns 65 in May. As part of the deal, Read has to stay on through at least next March and is barred from working with a competitor for a minimum of two years after that.
According to Bloomberg, Read’s compensation included in part a salary of $1.96 million, a $2.6 million bonus, $13.1 million in equity awards linked to financial goals and stock price, as well as an $8 million special equity award that will vest if the company’s average stock return goes above 25 percent for 30 consecutive trading days before then end of 2022.
Read 7 remaining paragraphs | Comments
Pfizer CEO gets 61% pay raise—to $27.9 million—as drug prices continue to climb published first on https://medium.com/@CPUCHamp
Tech Botic 
